Login / Signup

Discontinuation of Canakinumab following Clinical Disease Remission Is Feasible in Patients with Systemic Juvenile Idiopathic Arthritis.

Despoina N MaritsiOlga VougioukaDespina Eleftheriou
Published in: The Journal of rheumatology (2020)
Keyphrases
  • juvenile idiopathic arthritis
  • disease activity
  • systemic lupus erythematosus
  • rheumatoid arthritis
  • ulcerative colitis